Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis

ADVANCE was a 2-year, double-blind, placebo-controlled, Phase 3 study in 1512 patients aged 18–65 years with relapsing-remitting multiple sclerosis, which demonstrated that peginterferon beta-1a 125 mcg administered subcutaneously every 2 or 4 weeks led to significant reductions in annualized relaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Newsome, Scott D., Kieseier, Bernd C., Arnold, Douglas L., Shang, Shulian, Liu, Shifang, Hung, Serena, Sabatella, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010838/
https://www.ncbi.nlm.nih.gov/pubmed/27314959
http://dx.doi.org/10.1007/s00415-016-8182-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010838/
https://www.ncbi.nlm.nih.gov/pubmed/27314959
http://dx.doi.org/10.1007/s00415-016-8182-4

Ejemplares similares